St. Jude ICD Segment Improves 53% In Q2 Despite Competition From CRT
This article was originally published in The Gray Sheet
Executive Summary
St. Jude's pacing and ICD businesses have not been significantly affected by the recent launch of cardiac resynchronization devices from competitors Medtronic and Guidant
You may also be interested in...
SJM Epic Porcine Valve Trial Signals Turnaround Of St. Jude’s Valve Business
St. Jude expects the introduction of its BioCor stented porcine tissue valve in the U.S. later this year to lead a roughly 13% turnaround of the firm's replacement heart valve business in 2003
SJM Epic Porcine Valve Trial Signals Turnaround Of St. Jude’s Valve Business
St. Jude expects the introduction of its BioCor stented porcine tissue valve in the U.S. later this year to lead a roughly 13% turnaround of the firm's replacement heart valve business in 2003
St. Jude Relying On ICD Boom To Weather Slowdown In Pacer Sales
St. Jude continues to benefit from the rapidly expanding ICD market, although pacemaker sales are constrained by competition from cardiac resynchronization therapy (CRT) devices for congestive heart failure